Prenatal exposure to buprenorphine does not increase neurodevelopmental risk compared to methadone, according to a large-scale analysis of nationwide Medicaid data published in the BMJ.

The study, conducted by Friedrich and colleagues, compared neurodevelopmental outcomes in children exposed in utero to either buprenorphine or methadone during the first eight years of life. The findings carry direct clinical relevance for obstetric and addiction medicine providers weighing medication for opioid use disorder (MOUD) options in pregnant patients.

Opioid use disorder (OUD) during pregnancy is a condition of substantial clinical consequence. It is associated with overdose, preterm birth, neonatal complications, and maternal and fetal death. The condition has placed mounting pressure on health systems across the United States, including in Hawaii, where OUD intersects with broader substance use trends among reproductive-age patients. Standard clinical guidance from multiple authoritative bodies, including the Substance Abuse and Mental Health Services Administration, has long recognized methadone and buprenorphine as the two recommended pharmacotherapies for OUD during pregnancy.

Methadone has served as the standard of care for more than three decades. It’s a full opioid agonist administered through federally regulated opioid treatment programs, which require daily in-person dosing. Buprenorphine, a partial opioid agonist, can be prescribed in office-based settings, which reduces a patient’s treatment burden considerably. The pharmacological profile of buprenorphine, including a lower risk of sedation and respiratory depression relative to methadone, has driven a steady clinical migration toward its use in pregnancy. Early evidence had also suggested favorable neonatal outcomes with buprenorphine, including reduced severity of neonatal opioid withdrawal syndrome (NOWS).

Yet one question hadn’t been answered with confidence: what happens to the neurodevelopment of children exposed prenatally to these medications over the longer term? That gap is precisely what Friedrich and colleagues set out to address.

The study drew on nationwide Medicaid data from the United States, an administrative dataset with sufficient population scale to support meaningful subgroup analyses and longitudinal follow-up. Medicaid covers a substantial share of pregnancies in the US, making it a reasonable proxy for examining outcomes in low-income and publicly insured populations, groups that carry a disproportionate burden of OUD. The researchers tracked neurodevelopmental disorder diagnoses across the first eight years of life in children with documented prenatal exposure to either buprenorphine or methadone.

Reassuring. That word appears directly in the editorial commentary accompanying the study, and it’s warranted. Buprenorphine-exposed children did not show a higher risk of neurodevelopmental disorders relative to methadone-exposed children.

This matters for several reasons. Critics of MOUD in pregnancy have sometimes pointed to the absence of long-term pediatric outcome data as a reason for caution. The Friedrich analysis addresses that concern with a follow-up window of eight years. That’s not a brief postnatal checkup. Eight years encompasses language development, cognitive milestones, behavioral assessment, and school-age neurological evaluation.

The shift toward buprenorphine use in many clinical settings had already been underway before this evidence emerged. The American College of Obstetricians and Gynecologists has supported MOUD in pregnancy for years, acknowledging that untreated OUD poses greater risk than the risks associated with pharmacotherapy. But the neurodevelopmental question lingered. Clinicians who favored methadone on the basis of longer evidence history now have data suggesting buprenorphine doesn’t carry a measurable developmental penalty over the first eight years of life.

From an endocrinological and neurological standpoint, this is not a trivial finding. Opioid receptors are expressed throughout the developing central nervous system. Prenatal opioid exposure, whether from illicit use or from medically supervised MOUD, reaches fetal tissue. The concern about downstream neurodevelopmental effects, including risks of autism spectrum disorder, attention-deficit/hyperactivity disorder, language delays, and intellectual disability, has been a persistent and legitimate question for pediatric neurologists and developmental specialists alike. The Friedrich study’s eight-year follow-up is the most extended comparative data available for this specific clinical comparison.

It’s also worth situating this within the context of what’s already known about buprenorphine’s neonatal profile. Studies have generally shown that neonates exposed to buprenorphine in utero experience less severe NOWS than those exposed to methadone, with shorter hospital stays and lower rates of pharmacological NOWS treatment. This neonatal advantage had made buprenorphine an increasingly attractive option even before the neurodevelopmental data matured. The new analysis from Friedrich and colleagues extends that picture forward by years.

The study isn’t without limitations. Administrative claims data, even at nationwide scale, rely on diagnostic coding accuracy and can’t fully account for confounding variables such as polysubstance use, socioeconomic stress, prenatal care quality, or postnatal home environment, all factors that shape neurodevelopmental trajectories independently of MOUD exposure. The comparison is between two treated groups, not between treated and untreated groups, which means the study can’t quantify what neurodevelopmental risks might arise from untreated OUD during pregnancy. That comparison remains ethically and methodologically difficult to construct prospectively.

There are also population-level considerations specific to Hawaii and Pacific Island communities that the Medicaid dataset, though large, may not adequately capture. Native Hawaiian and Pacific Islander patients face documented barriers to OUD treatment access, including geographic isolation, cultural stigma around addiction treatment, and limited availability of certified opioid treatment programs on neighbor islands. Office-based buprenorphine prescribing, precisely because it doesn’t require daily clinic attendance, has practical advantages in these settings that methadone cannot match. The National Institute on Drug Abuse has recognized access disparities in OUD treatment as a significant public health concern, though Pacific Islander-specific data in large Medicaid analyses remains thin. Providers serving these communities should interpret the Friedrich findings as broadly applicable while recognizing that subgroup-level confirmation would strengthen the evidence base.

The BMJ analysis of the Friedrich study frames the findings as addressing a persistent evidence gap rather than closing the book on prenatal MOUD research. That framing is appropriate. The study doesn’t resolve all open questions. It doesn’t address what happens beyond age eight. It doesn’t disaggregate outcomes by specific neurodevelopmental diagnoses with the granularity that a prospective cohort might achieve. And it doesn’t tell clinicians much about children born to patients who switched between methadone and buprenorphine during pregnancy, a clinical scenario that happens with some regularity.

What it does provide is the clearest comparative neurodevelopmental evidence yet available for children followed through early childhood and into the school years. For clinicians managing OUD in pregnancy, the takeaway is direct: buprenorphine’s established neonatal advantages are not offset by longer-term neurodevelopmental costs when measured against methadone over an eight-year horizon.

The clinical implications for practice in Hawaii are real. Patients and providers who had been uncertain about buprenorphine on the grounds that its pediatric safety profile was insufficiently characterized now have a more complete evidential picture. Office-based buprenorphine prescribing expands access in ways that structured opioid treatment programs, with their daily attendance requirements, cannot always replicate in an archipelago state where interisland travel is a real barrier. That access advantage, combined with a comparable neurodevelopmental outcome profile, strengthens the case for buprenorphine as a first-line option in pregnant patients with OUD who can be managed in an office-based setting.

Providers should continue to individualize treatment decisions based on patient history, prior MOUD experience, access constraints, and clinical stability. Methadone remains an appropriate and evidence-supported option, particularly for patients with prior methadone treatment history or those whose clinical profile calls for the structured setting of a certified opioid treatment program. The Friedrich study does not argue against methadone. It argues that buprenorphine, where clinically indicated, doesn’t carry a measurable neurodevelopmental cost that should count against it.

Pregnant patients with OUD deserve pharmacotherapy that is both effective and safe across the full developmental arc of their children’s early lives. The data from Friedrich and colleagues move that standard of evidence forward by eight years of follow-up and a nationwide patient sample.